Intratunical Injection of Stromal vascular fraction prevents Fibrosis in a Rat Model of Peyronie's Disease.

Previous studies have shown that the injection of adipose tissue-derived stem cells (ADSCs) into the tunica albuginea (TA) during the active phase of the Peyronie's disease (PD) prevents the development of fibrosis and elastosis in the TA and corpus cavernosum The aim of this study was to investigate whether local injection of autologous adipose stromal vascular fraction (SVF) can prevent the development of fibrosis and elastosis in the TA using a rat model of acute phase of the Peyronie's disease (PD) METHODS: A total of 24 male 12-wk-old Sprague-Dawley rats were divided in three equal groups: sham, PD without treatment (TGFB) and PD treated with SVF (SVF) 1 day after disease induction. Sham rats underwent 2 injections of vehicle into the TA one day apart. TGFB rats underwent TGF- β1 injection and injection of vehicle one day later. SVF rats underwent TGF-β1 injection followed by SVF one day later. One month after treatment all rats underwent measurement of intracorporal pressure (ICP) and mean arterial (MAP) pressure during electrostimulation of the cavernous nerve. Following euthanasia, penises were again harvested for histology and Western blot.

Erectile function was moderately reduced in the TGFB group and was significantly improved after SVF treatment (p < 0.05). PD animals developed areas of fibrosis with a significant upregulation of collagen III, Collagen I and elastin protein expression. These fibrotic changes were prevented when treated with SVF.

Local injection of SVF may represent a treatment for the acute phase of PD. This article is protected by copyright. All rights reserved.

BJU international. 2018 Sep 29 [Epub ahead of print]

Fabio Castiglione, Petter Hedlund, Emmanuel Weyne, Lukman Hakim, Francesco Montorsi, Andrea Salonia, Trinity J Bivalacqua, Dirk De Ridder, Uros Milenkovic, David Ralph, Giulio Garaffa, Asif Muneer, Steven Joniau, Maarten Albersen, Trauma and Reconstructive Urology Working Party of the European Association of Urology (EAU) Young Academic Urologists (YAU)

Laboratory for Experimental Urology, Organ systems, Department of Development and Regeneration, University of Leuven, Leuven, Belgium., Department of Clinical and Experimental Pharmacology, Lund University, Sweden., Division of Oncology/Unit of Urology, Urological Research Institute IRCCS Ospedale San Raffaele, Milan, Italy., The James Buchanan Brady Urological Institute Department of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA., The Institute of Urology, University College of London Hospital (UCLH), London, UK.